As of today (2024-04-19), Myriad Genetics's share price is $18.49. Myriad Genetics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.63. Hence, Myriad Genetics's Price to Tangible Book Ratio of today is 11.36.
The historical rank and industry rank for Myriad Genetics's Price-to-Tangible-Book or its related term are showing as below:
MYGN'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.37 Med: 8.01 Max: 13.72
Current: 11.34
During the past 13 years, Myriad Genetics's highest Price to Tangible Book Ratio was 13.72. The lowest was 5.37. And the median was 8.01.
MYGN's Price-to-Tangible-Book is ranked worse than 90.53% of 169
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.52
vs MYGN: 11.34
A closely related ratio is called PB Ratio. As of today, Myriad Genetics's share price is $18.49. Myriad Genetics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $8.71. Hence, Myriad Genetics's P/B Ratio of today is 2.12.
Myriad Genetics Price-to-Tangible-Book Historical Data
The historical data trend for Myriad Genetics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myriad Genetics Annual Data
Trend
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
-
-
6.80
5.37
11.76
Myriad Genetics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
5.37
10.59
21.29
32.73
11.76
Competitive Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Price-to-Tangible-Book Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Myriad Genetics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Myriad Genetics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics (Myriad Genetics) Business Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your 